US allows increased production of Takeda’s ADHD drug to address shortage, ET HealthWorld

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

US allows increased production of Takeda’s ADHD ***** to address shortage, ET HealthWorld

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Bengaluru: The U.S. ***** Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical’s ADHD ***** Vyvanse and its generic versions by about 24 per cent to address the medicine’s ongoing shortage in the ******* States.

The raised production limit follows the Food and ***** Administration’s request in July, the DEA said in a notice on Tuesday.

Attention deficit hyperactivity disorder (ADHD) drugs have been in short supply for years. The FDA warned of a shortage of *******-based drugmaker Teva Pharmaceutical Industries’ Adderall in October 2022, troubled by manufacturing delays.

That led to a spike in demand and subsequent shortage of Takeda’s Vyvanse.

Vyvanse, also known as lisdexamfetamine, is classified by the DEA as a schedule II controlled substance, which is applied to drugs considered to have a high likelihood of being abused, and additional prescribing safeguards are put in place.

The production limit for lisdexamfetamine was increased by 6,236 kilograms (kg), which includes 1,558 kg to address increased domestic demand and 4,678 kg for increased foreign demand for finished dosage medications, according to the DEA.

“These adjustments are necessary to ensure that the ******* States has an adequate and uninterrupted supply of lisdexamfetamine to meet legitimate patient needs both domestically and globally,” DEA said.

US FDA approved generic versions of Vyvanse from 11 drugmakers, including U.S.-based drugmakers Mallinckrodt and Viatris, ***-based Hikma Pharmaceuticals, and Indian drugmaker Sun Pharmaceutical Industries, last year after Takeda lost exclusivity over the *****.

(Reporting by Mariam Sunny in Bengaluru; Editing by Vijay Kishore)

• Published On Sep 4, 2024 at 05:39 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Download ETHealthworld App

• Get Realtime updates
• Save your favourite articles

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Scan to download App
data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

This is the hidden content, please

• Sign In
• or
• Sign Up

#increased #production #Takedas #ADHD #***** #address #shortage #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up